BlinkLab Secures A$17.5M to Advance FDA Trial and Commercial Launch of AI-Powered Autism Diagnostic, Expands ADHD Program
JMM
BlinkLab Limited (ASX: BB1) a digital healthcare company developing AI-powered diagnostic technologies, has secured A$17.5 million in an oversubscribed placement to institutional and sophisticated investors, positioning the Company to accelerate regulatory milestones and commercialisation of its lead autism diagnostic platform while expanding into the significantly larger ADHD market.
The capital raise, priced at A$0.65 per share, marks a critical inflection point for BlinkLab as it advances toward FDA approval and market entry for BlinkLab Dx1, its smartphone-based diagnostic aid for autism.
Funding to Accelerate Regulatory Pathway and Commercial Readiness
Proceeds from the placement will be deployed across key value-driving initiatives, including completion of the Company’s pivotal FDA 510(k) registrational trial for autism, progression of CE marking and EU MDR approval processes, and expansion of its clinical pipeline into ADHD through its BlinkLab Dx2 platform.
BlinkLab is approaching late-stage regulatory readiness for Dx1, supported by strong pilot data that has exceeded FDA-agreed performance thresholds, and is now focused on generating real-world evidence while building commercial infrastructure in the United States.
Targeting a Large, Underserved Global Market
The Company is targeting a substantial unmet need in neurodevelopmental diagnostics, where autism and ADHD remain significantly underdiagnosed and characterised by long waiting times and subjective clinical assessments.
BlinkLab’s AI-driven, smartphone-based platform is designed to deliver scalable, objective diagnostic support, aligning with increasing regulatory and clinical adoption of digital biomarkers and artificial intelligence in healthcare.
Expansion into ADHD Broadens Platform Opportunity
In parallel with its autism program, BlinkLab will initiate U.S. clinical studies for Dx2, targeting ADHD — a materially larger patient population. The Company expects to leverage its existing platform infrastructure to expand its diagnostic suite with minimal incremental cost, strengthening its positioning as a multi-indication digital diagnostics platform.
Commenting on the Placement, BlinkLab’s Co-founder, Managing Director & CEO, Dr Henk- Jan Boele, stated:
“This capital raise is another major milestone for BlinkLab. It is a direct result of the incredible dedication shown by our team and our clinical partners. They have worked tirelessly for several years to advance this technology to its current stage, from developing the foundational science to successfully executing complex clinical studies within the promised timelines, a particularly challenging feat in the medtech and clinical trial environment. It has required an extraordinary level of commitment to ensure we deliver a robust software product that meets the highest clinical and regulatory standards.
As a medical doctor, I have seen first-hand the challenges families face in navigating the diagnostic journey for autism and other neurodevelopmental conditions. Long waiting times, subjective assessments, and variability in access to specialists create a significant burden on both patients and healthcare systems. BlinkLab Dx1 has been designed to directly address this unmet need by providing an objective, accessible, and scalable diagnostic tool that can support earlier identification and intervention.
With this funding, we are now well positioned to complete our pivotal U.S. study and progress toward FDA approval, while also advancing our European regulatory strategy. Importantly, it also enables us to expand into ADHD, where the need for better diagnostic tools is arguably even greater. We believe this is just the beginning of what our platform can achieve in transforming the way neurodevelopmental conditions are diagnosed and managed.
We extend our sincere gratitude to our investors and the excellent work by our Joint Lead Managers in this capital raise. Funding will enable BlinkLab to continue our exciting journey and deliver our milestones on schedule.”
Also commenting on the Placement, BlinkLab’s Chairman, Mr Brian Leedman, stated:
“We are very pleased with the strong support received for this placement, particularly from high-quality institutional investors who share our long-term vision. At this stage of the Company’s development, it is critical to build a register that is aligned with our strategy, especially as we prepare to enter the United States, the largest and most important healthcare market globally.
This capital raise not only strengthens our balance sheet but also establishes relationships with investors who understand the scale of the opportunity ahead and the significance of what BlinkLab is seeking to achieve. As we move closer to regulatory approval and commercialisation, having the right partners on the register becomes increasingly important.
We believe BlinkLab is entering a highly attractive phase of growth, supported by strong clinical progress, a clear regulatory pathway, and powerful sector tailwinds in digital health and AI-driven diagnostics. The Board looks forward to executing on this next stage and delivering long-term value for shareholders.”
About us:
BlinkLab Limited, a company founded by neuroscientists at Princeton University, over the past several years has fully developed a smartphone based diagnostic platform for autism, ADHD, schizophrenia, and other neurodevelopmental conditions. Our most advanced product is an autism diagnostic test that leverages the power of smartphones, AI and machine learning to deliver screening tests specifically designed for children as young as 18 months old. This marks a significant advancement, considering traditional diagnoses typically occur around five years of age, often missing the crucial early window for effective intervention. BlinkLab is led by an experienced management team and directors with a proven track record in building companies and vast knowledge in digital healthcare, computer vision, AI and machine learning. Our Scientific Advisory Board consists of leading experts in the field of autism and brain development allowing us to bridge most advanced technological innovations with groundbreaking scientific research.
Contact details:
Dr Henk-Jan Boele
Chief Executive Officer
[email protected]
+31 (0) 611 132 247